Compare · NVO vs UNCY
NVO vs UNCY
Side-by-side comparison of Novo Nordisk A/S (NVO) and Unicycive Therapeutics Inc. (UNCY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and UNCY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 1414.1x UNCY ($152.4M).
- Over the past year, NVO is down 12.1% and UNCY is up 28.8% - UNCY leads by 40.9 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 4 for UNCY).
- NVO has more recent analyst coverage (25 ratings vs 4 for UNCY).
- Company
- Novo Nordisk A/S
- Unicycive Therapeutics Inc.
- Price
- $48.65+3.65%
- $5.46+2.44%
- Market cap
- $215.46B
- $152.4M
- 1M return
- -2.08%
- +6.13%
- 1Y return
- -12.07%
- +28.81%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 4
- Recent ratings
- 25
- 4
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Unicycive Therapeutics Inc.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest UNCY
- Amendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.
- Unicycive Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
- SEC Form 10-Q filed by Unicycive Therapeutics Inc.
- Amendment: SEC Form 4 filed by Director Kenkare-Mitra Sara
- Amendment: SEC Form 4 filed by Director Laumas Sandeep
- Amendment: SEC Form SCHEDULE 13G/A filed by Unicycive Therapeutics Inc.
- Unicycive Therapeutics Inc. filed SEC Form 8-K: Other Events
- Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
- SEC Form DEFA14A filed by Unicycive Therapeutics Inc.